Pyxis Oncology price target lowered to $8 from $9 at Stifel

Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $8 from $9 and keeps a Buy rating on the shares. The firm is “encouraged” by management’s completion in Q1 of patient enrollment into the Phase 1 dose expansion study evaluating single agent MICVO, says the analyst, who modestly lowers the firm’s price target to reflect revised financing assumptions.